Ma Hao, Xu Dong, Liu Fei, Yao Qing
Department of Cardiovascular Surgery, Beijing Tiantan Hospital, Capital Medical University Beijing 100070, China.
Am J Transl Res. 2021 Nov 15;13(11):12421-12430. eCollection 2021.
Cardiovascular death is increasing year by year, and effective treatment is a challenging clinical problem at present. The application of nano materials has pointed to a new therapeutic direction for the clinical treatment of cardiovascular diseases, and preparation of nanoparticles (NPs) with PBCA as carrier material has become a trending spot in clinical research. In this study, we observed the influence of 17-estradiol nanoparticles (17-E2-NPs) on the inflammatory response of myocardial infarction (MI) and its regulatory effect on miR-302b. First of all, we enrolled MI patients and healthy controls, and preliminarily determined that miR-302b was highly expressed in MI and positively correlated with inflammation response. Then, we prepared 17-E2-NPs and purchased rats for modeling to analyze the underlying mechanism of action. The results showed that in rats treated with 17-E2-NPs, the expression of miR-302b and inflammatory cytokines decreased, the proliferation of cardiac fibroblasts reduced and the apoptosis rate increased. According to the above results, we conclude that 17-E2-NPs can inhibit the proliferation of cardiac fibroblasts, promote the apoptosis rate and reduce the inflammatory reaction of MI, via the downregulation of miR-302b, which may be one of the effective treatment schemes for MI in the future.
心血管疾病导致的死亡逐年增加,目前有效的治疗方法仍是一个具有挑战性的临床问题。纳米材料的应用为心血管疾病的临床治疗指明了新的治疗方向,以聚氰基丙烯酸正丁酯(PBCA)为载体材料制备纳米颗粒(NPs)已成为临床研究的热点。在本研究中,我们观察了17-β-雌二醇纳米颗粒(17-E2-NPs)对心肌梗死(MI)炎症反应的影响及其对miR-302b的调控作用。首先,我们招募了MI患者和健康对照,初步确定miR-302b在MI中高表达且与炎症反应呈正相关。然后,我们制备了17-E2-NPs,并购买大鼠进行建模以分析其潜在作用机制。结果显示,在接受17-E2-NPs治疗的大鼠中,miR-302b和炎性细胞因子的表达降低,心脏成纤维细胞的增殖减少,凋亡率增加。根据上述结果,我们得出结论,17-E2-NPs可通过下调miR-302b抑制心脏成纤维细胞的增殖,提高凋亡率并减轻MI的炎症反应,这可能是未来MI的有效治疗方案之一。